249 related articles for article (PubMed ID: 25366259)
1. CD95 and CD95L promote and protect cancer stem cells.
Ceppi P; Hadji A; Kohlhapp FJ; Pattanayak A; Hau A; Liu X; Liu H; Murmann AE; Peter ME
Nat Commun; 2014 Nov; 5():5238. PubMed ID: 25366259
[TBL] [Abstract][Full Text] [Related]
2. Death induced by CD95 or CD95 ligand elimination.
Hadji A; Ceppi P; Murmann AE; Brockway S; Pattanayak A; Bhinder B; Hau A; De Chant S; Parimi V; Kolesza P; Richards J; Chandel N; Djaballah H; Peter ME
Cell Rep; 2014 Apr; 7(1):208-22. PubMed ID: 24656822
[TBL] [Abstract][Full Text] [Related]
3. DICE: A novel tumor surveillance mechanism-a new therapy for cancer?
Peter ME
Cell Cycle; 2014; 13(9):1373-8. PubMed ID: 24690893
[TBL] [Abstract][Full Text] [Related]
4. The role of CD95 and CD95 ligand in cancer.
Peter ME; Hadji A; Murmann AE; Brockway S; Putzbach W; Pattanayak A; Ceppi P
Cell Death Differ; 2015 Apr; 22(4):549-59. PubMed ID: 25656654
[TBL] [Abstract][Full Text] [Related]
5. CD95 promotes tumour growth.
Chen L; Park SM; Tumanov AV; Hau A; Sawada K; Feig C; Turner JR; Fu YX; Romero IL; Lengyel E; Peter ME
Nature; 2010 May; 465(7297):492-6. PubMed ID: 20505730
[TBL] [Abstract][Full Text] [Related]
6. CD95 Stimulation with CD95L and DISC Analysis.
Le Gallo M; Legembre P
Methods Mol Biol; 2017; 1557():11-18. PubMed ID: 28078578
[TBL] [Abstract][Full Text] [Related]
7. CD95 ligand: lethal weapon against malignant glioma?
Weller M; Kleihues P; Dichgans J; Ohgaki H
Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.
Risso V; Lafont E; Le Gallo M
Cell Death Dis; 2022 Mar; 13(3):248. PubMed ID: 35301281
[TBL] [Abstract][Full Text] [Related]
9. CD95/Fas ligand induced toxicity.
Haluck-Kangas A; Peter ME
Biochem Soc Trans; 2023 Feb; 51(1):21-29. PubMed ID: 36629505
[TBL] [Abstract][Full Text] [Related]
10. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells.
Fulda S; Strauss G; Meyer E; Debatin KM
Blood; 2000 Jan; 95(1):301-8. PubMed ID: 10607716
[TBL] [Abstract][Full Text] [Related]
11. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1.
Schickel R; Park SM; Murmann AE; Peter ME
Mol Cell; 2010 Jun; 38(6):908-15. PubMed ID: 20620960
[TBL] [Abstract][Full Text] [Related]
12. CD95/Fas and metastatic disease: What does not kill you makes you stronger.
Guégan JP; Ginestier C; Charafe-Jauffret E; Ducret T; Quignard JF; Vacher P; Legembre P
Semin Cancer Biol; 2020 Feb; 60():121-131. PubMed ID: 31176682
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.
Watson GA; Naran S; Zhang X; Stang MT; Queiroz de Oliveira PE; Hughes SJ
Neoplasia; 2011 Mar; 13(3):198-205. PubMed ID: 21390183
[TBL] [Abstract][Full Text] [Related]
14. CD95 ligand induces senescence in mismatch repair-deficient human colon cancer via chronic caspase-mediated induction of DNA damage.
Raats DA; Frenkel N; van Schelven SJ; Rinkes IH; Laoukili J; Kranenburg O
Cell Death Dis; 2017 Mar; 8(3):e2669. PubMed ID: 28300842
[TBL] [Abstract][Full Text] [Related]
15. CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways.
Haymour L; Jean M; Smulski C; Legembre P
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189004. PubMed ID: 37865305
[TBL] [Abstract][Full Text] [Related]
16. CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.
Qadir AS; Ceppi P; Brockway S; Law C; Mu L; Khodarev NN; Kim J; Zhao JC; Putzbach W; Murmann AE; Chen Z; Chen W; Liu X; Salomon AR; Liu H; Weichselbaum RR; Yu J; Peter ME
Cell Rep; 2017 Mar; 18(10):2373-2386. PubMed ID: 28273453
[TBL] [Abstract][Full Text] [Related]
17. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L.
Aragane Y; Kulms D; Metze D; Wilkes G; Pöppelmann B; Luger TA; Schwarz T
J Cell Biol; 1998 Jan; 140(1):171-82. PubMed ID: 9425165
[TBL] [Abstract][Full Text] [Related]
18. FasR and FasL in colorectal cancer.
Szarynska M; Olejniczak A; Wierzbicki P; Kobiela J; Laski D; Sledzinski Z; Adrych K; Guzek M; Kmiec Z
Int J Oncol; 2017 Sep; 51(3):975-986. PubMed ID: 28766682
[TBL] [Abstract][Full Text] [Related]
19. CD95/Fas ligand mRNA is toxic to cells.
Putzbach W; Haluck-Kangas A; Gao QQ; Sarshad AA; Bartom ET; Stults A; Qadir AS; Hafner M; Peter ME
Elife; 2018 Oct; 7():. PubMed ID: 30324908
[TBL] [Abstract][Full Text] [Related]
20. CD95 signaling in cancer treatment.
De la Rosa AJ; Gomez MA; Morales S; Padillo FJ; Muntane J
Curr Pharm Des; 2014; 20(17):2809-18. PubMed ID: 23944368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
